Compumedics Limited (ASX: CMP) announced that it has achieved record sales orders of approximately AU$ 52 million and has shipped record revenues of roughly AU$ 49 million for the fiscal year 2024, pending audit. The company attributes this strong sales performance to growth in the Australian sleep and neurodiagnostic businesses, receiving two new MEG orders totaling AU$9.2 million in December 2023 and increased sales in European sleep and neurodiagnostics. Additionally, European solid sales were driven by Okti, the world's first wireless EEG amplifier, with significant sites in Germany secured.
The company is also seeing substantial results from its efforts to develop the USA market, with a 67% growth in sales orders during the second half of FY24 compared to the first half. Compumedics Limited also expects to surpass the first half of FY24 EBITDA of AU$2.2 million. Sales orders for Somfit showed a 133% improvement in FY24, AU$2.1 million, over FY23, $ 0.9 million.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 20, 2024
Nov 20, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
